305 related articles for article (PubMed ID: 18499307)
1. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.
Zhan X; Slobod KS; Krishnamurthy S; Luque LE; Takimoto T; Jones B; Surman S; Russell CJ; Portner A; Hurwitz JL
Vaccine; 2008 Jun; 26(27-28):3480-8. PubMed ID: 18499307
[TBL] [Abstract][Full Text] [Related]
2. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.
Jones B; Zhan X; Mishin V; Slobod KS; Surman S; Russell CJ; Portner A; Hurwitz JL
Vaccine; 2009 Mar; 27(12):1848-57. PubMed ID: 19200447
[TBL] [Abstract][Full Text] [Related]
3. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B.
Zhan X; Hurwitz JL; Krishnamurthy S; Takimoto T; Boyd K; Scroggs RA; Surman S; Portner A; Slobod KS
Vaccine; 2007 Dec; 25(52):8782-93. PubMed ID: 18037543
[TBL] [Abstract][Full Text] [Related]
5. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
6. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
[TBL] [Abstract][Full Text] [Related]
7. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
Mason JN; Elbahesh H; Russell CJ
J Virol; 2013 May; 87(10):5959-69. PubMed ID: 23514887
[TBL] [Abstract][Full Text] [Related]
8. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
9. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.
Scaggs Huang F; Bernstein DI; Slobod KS; Portner A; Takimoto T; Russell CJ; Meagher M; Jones BG; Sealy RE; Coleclough C; Branum K; Dickey M; Buschle K; McNeal M; Makowski M; Nakamura A; Hurwitz JL
Hum Vaccin Immunother; 2021 Feb; 17(2):554-559. PubMed ID: 32750273
[TBL] [Abstract][Full Text] [Related]
11. Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.
Zhan X; Slobod KS; Jones BG; Sealy RE; Takimoto T; Boyd K; Surman S; Russell CJ; Portner A; Hurwitz JL
Int Immunol; 2015 May; 27(5):229-36. PubMed ID: 25477211
[TBL] [Abstract][Full Text] [Related]
12. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.
Jones BG; Sealy RE; Rudraraju R; Traina-Dorge VL; Finneyfrock B; Cook A; Takimoto T; Portner A; Hurwitz JL
Vaccine; 2012 Jan; 30(5):959-68. PubMed ID: 22119594
[TBL] [Abstract][Full Text] [Related]
13. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
[TBL] [Abstract][Full Text] [Related]
14. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
J Virol; 2017 May; 91(10):. PubMed ID: 28250126
[TBL] [Abstract][Full Text] [Related]
15. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections.
Hurwitz JL
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S126-8. PubMed ID: 18820573
[TBL] [Abstract][Full Text] [Related]
16. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
17. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
18. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector.
Wiegand M; Gori-Savellini G; Martorelli B; Bossow S; Neubert WJ; Cusi MG
Vaccine; 2013 Aug; 31(37):3888-93. PubMed ID: 23831325
[TBL] [Abstract][Full Text] [Related]
20. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A
J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]